An observational study in Hepatitis B, Chronic, sponsored by Hong Ren. Status unknown at 1 site in China. Per ClinicalTrials.gov, last updated 2021-09-27.
Sponsored by Hong Ren · Observational
HBV(hepatitis B virus) with metabolic comorbidities may accelerate liver disease progression and increase the risk of HCC(Hepatocellular Carcinoma)development. It is reported combination of metabolic diseases and CHB is associated with substantially increased rates of liver cirrhosis and secondary liver-related events compared to CHB alone. Consequently, hepatitis B patients with metabolic comorbidities warrant particular attention in disease surveillance and evaluation of treatment indications.
Primary objective:
To evaluate the impact of metabolic disease on the progression of chronic hepatitis B
Group 1 : CHB with diabetes Group 2 : CHB with hyperlipemia Group 3 : CHB without metabolic diseases
Study Duration (in months) 24 months
1,656 studies on the registry are indexed under Hepatitis B; 196 are open to participants now.
This study's planned enrollment of 10,000 is above the median of 390 across 407 observational studies indexed under Hepatitis B.
Browse Hepatitis B studies →Hong Ren is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Chronic hepatitis B patients
Exclusion Criteria:
* HBsAg(+) patients * TC\>5.17mmol/L（200mg/dl）and（or）TG\>2.3mmol/L（200mg/dl）
* HBsAg(+) patients * FPG\>126 mg/dL(7.0 mmol/L)Fasting is defined as no caloric intake for at least 8 h.
* HBsAg(+) patients * without diabetes/ obesity/hyperlipidemia
Efficacy of NAs therapy
We will follow up patients every six months and all patients with a history of hepatitis B will be tested for HBsAg(+) and HBD-DNA.The curative effect was evaluated by observing the changes of serological indexes.
Time frame: 2 year
Incidence of liver fibrosis and cirrhosis
We will follow up patients every six months and all patients() with a history of hepatitis B will be tested for FibroScan. The influence of metabolic diseases on the progression of hepatitis B was evaluated by comparing the changes of liver hardness between groups（Hyperlipidemia，Diabetes and CHB without metabolic disease）
Time frame: 2 year
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hong Ren